The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections
Open accessAbstract
Bacterial infection remains one of the leading causes of death worldwide, and the options for treating such infections are decreasing, due the rise of antibiotic-resistant bacteria. The pharmaceutical industry has produced few new types of antibiotics in more than a decade. Researchers are taking several approaches toward developing new classes of antibiotics, including (1) focusing on new targets and processes, such as bacterial cell-cell communication that upregulates virulence; (2) designing inhibitors of bacterial resistance, such as blockers of multidrug efflux pumps; and (3) using alternative antimicrobials such as bacteriophages. In addition, the strategy of finding new uses for existing drugs is beginning to produce results: antibacterial properties have been discovered for existing anticancer, antifungal, anthelmintic, and anti-inflammatory drugs. In this review, we discuss the antimicrobial properties of gallium compounds, 5-fluorouracil, ciclopirox, diflunisal, and some other FDA-approved drugs and argue that their repurposing for the treatment of bacterial infections, including those that are multidrug resistant, is a feasible strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
Vermes, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.171 · Cited by 803
Gallium Disrupts Iron Metabolism of Mycobacteria Residing within Human Macrophages
Olakanmi, O., Britigan, B. E., & Schlesinger, L. S. (2000) · Infection and Immunity · doi:10.1128/iai.68.10.5619-5627.2000 · Cited by 220 · cited 2×
“Inhibition of Fe(III) transport by Ga was first demonstrated for intraphagosomal M. tuberculosis (Olakanmi et al., 2000).”
BackgroundGallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment
Ross-Gillespie, A., Weigert, M., Brown, S. P., & Kümmerli, R. (2014) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eou003 · Cited by 104
Carlson-Banning, K. M., Chou, A., Liu, Z., Hamill, R. J., Song, Y., & Zechiedrich, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069646 · Cited by 73
Cited by
Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options
Chatterjee, M., Anju, C. P., Biswas, L., Anil Kumar, V., Gopi Mohan, C., & Biswas, R. (2016) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2015.11.004 · Cited by 312
Gallium and its competing roles with iron in biological systems
Chitambar, C. R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.04.027 · Cited by 274
Drug repurposing to fight colistin and carbapenem-resistant bacteria
Peyclit, L., Baron, S. A., & Rolain, J.-M. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00193 · Cited by 91
Wambaugh, M. A., Shakya, V. P. S., Lewis, A. J., Mulvey, M. A., & Brown, J. C. S. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2001644 · Cited by 63
Metadata
- Authors
- Rangel-Vega, A., Bernstein, L. R., Mandujano-Tinoco, E. A., GarcÃa-Contreras, S. J., & GarcÃa-Contreras, R.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2015-04-09
- Volume
- 6
- Pages
- 282-282
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W2078957489
- Cited by
- 168
- References
- 5
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.